Stock WVE WAVE LIFE SCIENCES LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Wave Life Sciences Ltd.

Equities

WVE

SG9999014716

Market Closed - Nasdaq
Other stock markets
 04:30:01 2024-05-03 pm EDT 		5-day change 1st Jan Change
6.14 USD +4.42% Intraday chart for Wave Life Sciences Ltd. +31.76% +21.58%
Apr. 30 Wave Life Sciences Announces Approval of First Clinical Trial Application for RestorAATion-2 Trial of WVE-006 in Individuals with Alpha-1 Antitrypsin Deficiency CI
Apr. 23 Wave Life Sciences Ltd. Announces Continued Momentum in GSK Collaboration and Advancements in siRNA and RNA Editing CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Wave Life Sciences First Quarter 2024 Financial Results Scheduled for May 9, 2024
GL
Wave Life Sciences Announces Approval of First Clinical Trial Application for RestorAATion-2 Trial of WVE-006 in Individuals with Alpha-1 Antitrypsin Deficiency (AATD)
GL
Wave Life Sciences Announces Continued Momentum in GSK Collaboration and Advancements in siRNA and RNA Editing
GL
Wave Life Sciences to Present at Upcoming Investor Conferences
GL
Wave Life Sciences: Q4 Earnings Snapshot
AQ
Wave Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
GL
Wave Life Sciences Fourth Quarter and Full Year 2023 Financial Results Scheduled for March 6, 2024
GL
Wave Life Sciences Announces Upcoming Presentations at MDA Conference that Highlight Best-in-Class Potential for WVE-N531 in Duchenne Muscular Dystrophy
GL
Wave Life Sciences Highlights Recent Achievements and Upcoming 2024 Milestones
GL
Wave Life Sciences to Present at 42nd Annual J.P. Morgan Healthcare Conference
GL
Wave Life Sciences Announces Initiation of Dosing in Phase 2 FORWARD-53 Trial of WVE-N531 in Duchenne Muscular Dystrophy
AQ
Wave Life Sciences Announces Initiation of Dosing in Phase 2 FORWARD-53 Trial of WVE-N531 in Duchenne Muscular Dystrophy
GL
Wave Life Sciences Prices $100 Million Public Offering of Ordinary Shares
GL
Wave Life Sciences Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants
GL
Wave Life Sciences Announces Initiation of Dosing in RestorAATion Clinical Program Evaluating First-Ever RNA Editing Candidate, WVE-006, for Alpha-1 Antitrypsin Deficiency
GL
Wave Life Sciences to Present at 6ᵗʰ Annual Evercore ISI HealthCONx Conference
GL
Wave Life Sciences: Q3 Earnings Snapshot
AQ
Wave Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update
GL
Wave Life Sciences Third Quarter 2023 Financial Results Scheduled for November 9, 2023
GL
Wave Life Sciences Highlights Growth Strategy for Building the Leading RNA Medicines Company in Annual R&D Day
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. WVE Stock
  4. News Wave Life Sciences Ltd.
  5. Press Releases